Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors

Joan D. Beckman, Raj S. Kasthuri, Alisa S. Wolberg, Alice D. Ma

Research output: Contribution to journalLetterpeer-review

10 Scopus citations
Original languageEnglish (US)
Pages (from-to)e417-e420
Issue number6
StatePublished - Nov 2018

Bibliographical note

Funding Information:
This study was supported by research funding from the National Institutes of Health (R01HL126974 to ASW and T32HL007149 to the University of North Carolina and JDB) and a 2016 Mentored Research Award from the Hemostasis and Thrombosis Research Society (HTRS) to JDB which was sponsored by an educational grant to HTRS from CSL Behring. CSL Behring provided funds to HTRS for the Mentored Research Award programme but had no input into selection of awardees. CSL Behring had no direct in‐ teraction with the authors regarding the design or results of the study. ASW reports funding from Novo Nordisk outside the sub‐ mitted work. ADM reports personal fees from Shire, CSL Behring and Novo Nordisk outside the submitted work. The authors have no other conflicts of interest.

Funding Information:
The authors thank Dr. Nigel S. Key, Sheh-Li Chen and the staff of the University of North Carolina Hemophilia Treatment Center for their assistance obtaining the patient samples.

Cite this